ADS024

Changing the

Course of

Alzheimer's Disease

Changing the

Course of

Alzheimer's Disease

Changing the

Course of

Alzheimer's Disease

Changing the

Course of

Alzheimer's Disease

IMPACTING LIVES

Alzheimer’s disease is a devastating disease with a high personal and economic burden on individuals and their families. There is a significant need for new therapies.

Adiso’s goal is to develop oral medicines to slow the progression of Alzheimer’s disease. We seek to help patients have healthier, more productive lives.

Alzheimer’s disease is a devastating disease with a high personal and economic burden on individuals and their families. There is a significant need for new therapies.

Adiso’s goal is to develop oral medicines to slow the progression of Alzheimer’s disease. We seek to help patients have healthier, more productive lives.

Alzheimer’s disease is a devastating disease with a high personal and economic burden on individuals and their families. There is a significant need for new therapies.

Adiso’s goal is to develop oral medicines to slow the progression of Alzheimer’s disease. We seek to help patients have healthier, more productive lives.

A NEW FRONTIER IN ALZHEIMER'S

Adiso is focused on first-in-class agents with defined mechanisms of action and is targeting untapped pathways to modify the progression of Alzheimer’s disease and other neurodegenerative and neuroinflammatory diseases.

HALTING NEURODEGENERATION

In Alzheimer’s disease, aberrant lipid metabolism coincides with mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation. In concert with beta amyloid and tau pathologies, these processes lead to neurodegeneration and brain atrophy.

Adiso is developing novel agents to halt the advancement of these processes.

HOW THE LEAD CANDIDATE, ADS024, WORKS

Targeting LPAR3, a Class A GPCR
Adiso’s lead candidate, ADS024, produces a metabolite that potently agonizes the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).

The Gut-Brain-Immune Axis

ADS024 delivers the LPAR3 agonist through the gut-brain-immune axis to halt neurodegeneration.

Targeting LPAR3, a Class A GPCR
Adiso’s lead candidate, ADS024, produces a metabolite that potently agonizes the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).

The Gut-Brain-Immune Axis

ADS024 delivers the LPAR3 agonist through the gut-brain-immune axis to halt neurodegeneration.

Targeting LPAR3, a Class A GPCR
Adiso’s lead candidate, ADS024, produces a metabolite that potently agonizes the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).

The Gut-Brain-Immune Axis

ADS024 delivers the LPAR3 agonist through the gut-brain-immune axis to halt neurodegeneration.

Learn more about ADS024